Also, SVP Paul M. Silva sold 2,577 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, June 21st. Dai Ichi Life Insurance Company Ltd's holdings in Vertex Pharmaceuticals were worth $3,732,000 as of its most recent SEC filing.
Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. Baillie Gifford & Co. grew its holdings in shares of Vertex Pharmaceuticals by 6.9% during the second quarter. It dropped, as 48 investors sold Vertex Pharmaceuticals Incorporated shares while 165 reduced holdings. Tocqueville Asset Management L.P. purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at about $203,000. About shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since September 12, 2016 and is uptrending. Vanguard Group Inc. raised its holdings in Vertex Pharmaceuticals by 3.5% during the 1st quarter. The stock was trading on below-average volume. Capital Fund Management S.A. grew its holdings in shares of Vertex Pharmaceuticals by 17.4% during the second quarter. Capital World Investors now owns 22,292,383 shares of the pharmaceutical company's stock valued at $1,944,119,000 after buying an additional 599,586 shares during the period.
07/19/2017 - Vertex Pharmaceuticals Incorporated had its "buy" rating reiterated by analysts at Needham & Company. Finally, Argus boosted their price target on shares of Vertex Pharmaceuticals from $71.46 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, August 1st.
The stock decreased 0.64% or $1.02 during the last trading session, reaching $157.81.
According to the the latest analyst ratings which have been released, 9 brokers have issued a rating of "buy", 11 brokers "outperform", 5 brokers "hold", 0 brokers "underperform" and 0 brokers "sell". Vertex Pharmaceuticals has an average rating of "Buy" and a consensus target price of $162.88.
TRADEMARK VIOLATION WARNING: This story was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & worldwide trademark & copyright legislation.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at 156.82 on Wednesday. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 1.80 as current ratio and on the opponent side the debt to equity ratio was 0.81 and long-term debt to equity ratio also remained 0.77. The stock has a 50 day moving average price of $155.51 and a 200-day moving average price of $124.66. Putnam Invests Lc stated it has 0.07% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.33. The company had revenue of $544.10 million for the quarter, compared to analysts' expectations of $489.95 million. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%. VRTX generated revenue of $648.98 Million in the same quarter, one year ago. During the same quarter in the prior year, the firm earned $0.24 EPS. Equities analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current year. The stock was sold at an average price of $133.36, for a total transaction of $343,668.72. Following the transaction, the chief marketing officer now directly owns 125,949 shares of the company's stock, valued at approximately $16,096,282.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28,320 shares were sold by Arbuckle Stuart A, worth $3.38M on Friday, April 28. The price/earnings to growth ratio (PEG ratio) is a stock's price-to-earnings (P/E) ratio divided by the growth rate of its earnings for a specified time period. The disclosure for this sale can be found here. (NASDAQ:EBAY) established that the company was able to keep return on investment at - in the trailing twelve month while Reuters data showed that industry's average stands at 5.27 and sector's optimum level is 15.20.
Vertex Pharmaceuticals Incorporated's insider ownership stands at 0.5 percent, while its insider transaction is -52.22 percent.